Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 6
Submit an article Journal homepage
107
Views
64
CrossRef citations to date
0
Altmetric
Review

Recent advances in histamine H3/H4 receptor ligands

Holger Stark Institut für Pharmazeutische Chemie, Johann Wolfgang Goethe-Universität, Biozentrum, Marie-Curie-Strasse 9, 60439 Frankfurt am Main, Germany. [email protected]
Pages 851-865 | Published online: 02 Mar 2005

Bibliography

  • ARRANG JM, GARBARG M, SCHWARTZ JC: Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptors. Nature (1983) 302:832–837.
  • •First description of the histamine H3 receptor.
  • SCHLICKER E, MALINOWSKA B, KATHMANN M, GOTHERT M: Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundarn. Clin. Pharmacol (1994) 8(2):128–137.
  • •Recommendable view on heteroreceptor function of H3 receptors.
  • WATANABE T, TIMMERMAN H, YANAI K (Eds). Histamine research in the new millenium. Elsevier Science Publishers, Amsterdam, The Netherlands (2001).
  • ••Important collection of the latest findings inhistamine research.
  • CHOTARD C, OUIMET T, MORISSET S, SAHM U, SCHWARTZ JC, TROTTIER S: Effects of histamine H3 receptor agonist and antagonist on histamine co-transmitter expression in rat brain. J. Neural. Transm. (2002) 109(3):293–306.
  • LEURS R, SMIT MJ, TIMMERMAN H: Molecular pharmacological aspects of histamine receptors. Pharmacol Ther. (1995) 66(3):413–463.
  • LOVENBERG TW, ROLAND BL, WILSON SJ et al: Cloning and functional expression of the human histamine H3 receptor. MM. Pharmacol (1999) 55(6):1101–1107.
  • ••Cloning of hH3 receptor.
  • SCHWARTZ JC, MORISSET S, ROULEAU A et al.: Application of genomics to drug design: the example of the histamine H3 receptor. Eur. Neuropsychopharmacol (2001) 11(6):441–448.
  • •Recommendable review on a variety of H3 receptor aspects.
  • BAKKER RA, TIMMERMAN H, LEURS R: Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin. Allergy Immunol (2002) 17:27–64.
  • CHAZOT PL, HANN V: Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS? Curt: Opin. Awestik. Drugs (2001) 2(10):1428–1431.
  • WELLENDORPH P, GOODMAN MW, BURSTEIN ES, NASH NR, BRANN MR, WEINER DM: Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H3 receptor. Neuropharmacology (2002) 42(7):929–940.
  • ••Paper showing detailed pharmacology of H3receptor isoforms and screening of numerous neuropsychiatric drugs.
  • PILLOT C, HERON A, COCHOIS V et al.: A detailed mapping of the histamine H3 receptor and its gene transcripts in rat brain. Neuroscience (2002) 114(1):173–193.
  • GOMEZ-RAMIREZ J, ORTIZ J, BLANCO I: Presynaptic H3 autoreceptors modulate histamine synthesis through eAMP pathway. MM. Pharmacol (2002) 61(1):239–245.
  • DRUTEL G, PEITSARO N, KARLSTEDT K et al: Identification of rat H3 receptor isoforms with different brain expression and signaling properties. Ma Pharmacol (2001) 59(1):1–8.
  • •Differences in H3 receptor isoforms.
  • MORISSET S, ROULEAU A, LIGNEAU X et al.: High constitutive activity of native H3 receptor regulates histamine neurones in brain. Nature (2000) 408:860–864.
  • ••First paper describing high constitutive activity of H3 receptors in vivo and of a neutral antagonist and inverse agonists.
  • WIELAND K, BONGERS G, YAMAMOTO Y et al.: Constitutive activity of histamine H3 receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H3 antagonists. Pharmacol Exp. Ther (2001) 299(3):908–914.
  • •Constitutive activity and inverse agonism.
  • ROULEAU A, LIGNEAU X, TARDIVEL-LACOMBE J et al.: Histamine H3-receptor-mediated [355]-GTPy[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br. J. Pharmacol (2002) 135(2):383–392.
  • ODA T, MORIKAWA N, SAITOY, MASUHO Y, MATSUMOTO S: Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. (2000) 275(47):36781–36786.
  • ••Cloning of hH4 receptor.
  • HOUGH LB: Genomics meets histamine receptors: new subtypes, new receptors. Pharmacol Exp. The]: (2001) 59(3):415–419.
  • •Short summary of actual genomic investigation on H3 and H4 receptors.
  • STARK H, SCHLEGEL B, SIPPL W: News on old histamine I. A new member in the receptor family. Pharm. Unsere Zeit(2003) 32:92–93.
  • COGE F, GUENIN SP, RIQUE H, BOUTIN JA, GALAZZI JP: Structure and expression of the human histamine RI-receptor gene. Biochem. Biophys. Res. Comm. (2001) 284:301–309.
  • SIROIS J, MENARD G, MOSES AS, BISSONNETTE EY: Importance of histamine in the cytokine network in the lung through H2 and H3 receptors: stimulation of IL-10 production. I Immunol (2000) 164(6):2964–2970.
  • SCHNEIDER E, ROLLI- DERKINDEREN M, AROCK M, DY M: Trends in histamine research: new functions during immune responses and hematopoiesis. Trends Immunol (2002) 23(5):255–263.
  • ••Recommendable discussion on H3 and H4receptor aspects in immune system and haematopoisis.
  • TOZER MJ, KALINDJIAN B: Histamine H3 receptor antagonists. Expert Opin. Ther. Patents (2000) 10(7):1045–1055.
  • •Recommendable review on the H3 receptor antagonist and patent situation.
  • STARK H, ARRANGJM, LIGNEAU X et al.: The histamine H3 receptor and its ligands. Frog. Med. Chem. (2001) 38:279–308.
  • ••Recommendable review on histamine H3receptor ligands.
  • BROWN RE, STEVENS DR, HAAS HL: The physiology of brain histamine. Frog. Neurobiol (2001) 63(6):637–672.
  • ••Recommendable review on physiologicalaspects of brain histamine.
  • LEURS R, BLANDINA P, TEDFORD C, TIMMERMAN H: Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci. (1998) 19(5):177–183.
  • ••Recommendable short review ontherapeutic aspects of H3 receptor ligands.
  • HAAS H, PANULA P: The role of histamine and the tuberomamillary nucleus in the nervous system. Nat. Rev Neurosci. (2003) 4:121–130.
  • ••Recommendable review on histarninergicinnervation within the tuberomarnillary nucleus.
  • LIPP R, STARK H, SCHUNACK W: Pharmacochemistry of H3-receptors. In: Biochemistry and Methology (Volume 16). The Histamine Receptor. Schwartz JC, Haas HL (Eds), Wiley-Liss, New York (1992):57–72.
  • SASSE A, SADEK B, LIGNEAU X et al.: New histamine H3-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency. [Med. Chem. (2000) 43(17):3335–3343.
  • ARRANG JM, GARBARG M, LANCELOT JC et al.: Highly potent and selective ligands for histamine H3-receptors. Nature (1987) 327(6118):117–123.
  • ••First paper describing selective ligands forH3 receptors.
  • VAN DER GOOT H, SCHEPERS MJP, STREK GJ, TIMMERMAN H: Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3-receptor. Eur: J. Med. Chem. (1992) 27:511–517.
  • STARK H, SADEK B, KRAUSE M et al.: Novel histamine H3-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propy1)-1H-imidazole structures like ciproxifan and related compounds. J. Med. Chem. (2000) 43(21):3987–3994.
  • LIGNEAU X, UN J, VANNI-MERCIER G et al.: Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J. Pharmacol Exp. The]: (1998) 287(2):658–666.
  • STARK H. Convenient procedures for synthesis of ciproxifan, a histamine H3-receptor antagonist. Arch. Pharm. (Weinheim) (2000) 333(9):315–316.
  • VOLLINGA RC, DE KONING JP, JANSEN FP, LEURS R, MENGE WM, TIMMERMAN H: A new potent and selective histamine H3 receptor agonist, 4- (1H-imidazol-4-ylmethyl)piperidine. Med. Chem. (1994) 37(3):332–333.
  • MARTINEZ AC, PRIETO D, HERNANDEZ M, GARCIA-SACRISTAN A, BENEDITO S: Contractile response of horse deep dorsal penile vein to histamine. Int. I Impot. Res. (2002) 14(2):85–92.
  • SILVER RB, POONWASI KS, SEYEDI N, WILSON SJ, LOVENBERG TW, LEVI R: Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc. Nati Acad. Sci. USA (2002) 99(1):501–506.
  • SILVER RB, MACKINS CJ, SMITH NC et al.: Coupling of histamine H3 receptors to neuronal Na±/H+ exchange: a novel protective mechanism in myocardial ischemia. Proc. Nati Acad. Sci. USA (2001) 98(5):2855–2859.
  • LEVI R, SMITH NCE: Histamine H3-receptors: a new frontier in myocardial ischemia. Pharmacol Exp. Ther. (2000) 292:825–830.
  • •Recommendable paper describing cardiac functions of H3 receptors.
  • MACKINS CL, LEVI R: Therapeutic potential of H3-receptor agonists in myocardial infarction. Expert Opin. Investig. Drugs (2000) 9(11):2537–2542.
  • MORINI G, TIMMERMAN H, SCHUNACK W, GRANDI D: Agonists for the histamine H3-receptor differ in their gastroprotective activity in the rat. Inflamm. Res. (2002) 51\(Supp1.1):S75–S76.
  • MORINI G, GRANDI D, STARK H, SCHUNACK W: Histamine H3-receptor antagonists inhibit gastroprotection by N-a-methylhistamine in the rat. Br. J. Pharmacol (2000) 129(8):1597–1600.
  • PANULA P, LINTUNEN M, KARLSTEDT K: Histamine in brain development and tumors. Semin. Cancer Biol. (2000) 10(1):11–14.
  • MORINI G, GRANDI D, SCHUNACK W: Ligands for histamine H3 receptors modulate cell proliferation and migration in rat oxyntic mucosa. Br: J. Pharmacol. (2002) 137(2):237–244.
  • POLI E, POZZOLI C, CORUZZI G: Role of histamine H3 receptors in the control of gastrointestinal motility. An overview. .1. Physiol Paris (2001) 95(1–6):67–74.
  • SCHWARTZ JC, ARRANGJM: Histamine. In: Neuropsychopharmacology: the fifth generation of progress Davis KL, Charney D, Coyle JT, Nemeroff C (Eds), Lipincott, Williams & Wilkins, Philadelphia, USA (2002):179–190.
  • ••Recommendable paper on neuropsychiatric functions of H3 receptor ligands.
  • ROULEAU A, STARK H, SCHUNACK W, SCHWARTZ JC: Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H3-receptor agonist prodrug. Pharmacol. Exp. Ther. (2000) 295(1):219–225.
  • •First paper on H3 receptor agonist pro-drugs.
  • CANNON KE, NALWALK JW, STADEL R et al.: Spinal H3-receptor activation induces mechanical but not thermal antinociception. Program No. 54.1 2002 Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, DC, USA (2002) CD-ROM.
  • MONTI JM, JANTOS H, PONZONI A, MONTI D: Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology (1996) 15(1):31–35.
  • JACOBS EH, YAMATODANI A, TIMMERMAN H: Is histamine the final neurotransmitter in entrainment of circadian rhythms in mammals? Trends Pharmacol Sci. (2000) 21:293–298.
  • •Description of histarninergic functions in waking and sleep control.
  • MATSUBARA T, MOSKOWITZ MA, HUANG Z: UK-14,304, R( ) a methyl-histamine and SMS 201-995 block plasma protein leakage within dura mater by prejunctional mechanisms. Eur. Pharmacol (1992) 224(2-3):145–150.
  • •Recommendable paper on H3 receptor agonists in migraine.
  • GUERRERO RO, CARDENAS MA, OCAMPO AA, PACHECO MF: Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache (1999) 39(8):576–580.
  • BEZARD E, BROTCHIE JM, GROSS CE: Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. (2001) 2 (8) :577–588.
  • HUOTARI M, KUKKONEN K, LIIKKA N, POTASEV T, RAASMAJA A, MANNISTO PT: Effects of histamine H3-ligands on the levodopa-induced turning behavior of hemiparkinsonian rats. Parkinsonism Relat. Bison-I. (2000) 6(3):159–164.
  • ITO C: The role of brain histamine in acute and chronic stresses. Biomed. Pharmacother. (2000) 54(5):263–267.
  • NATH C, GUPTA MB: Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem. Behav. (2001) 68(4):777–782.
  • RUBIO S, BEGEGA A, SANTIN LJ, ARIAS JL: Improvement of spatial memory by W-a-methylhistamine, a histamine H3-receptor agonist, on the Morris water-maze in rat. Behav. Brain Res. (2002) 129(1-2):77–82.
  • FOZARD JR: BP-294 Ste Clyne Bioprojet. Curr. Opin. Investig. Drugs(2000)1(1):86–89.
  • KRAUSE M, STARK H, SCHUNACK W: Azomethine prodrugs of (h) -a-methylhistamine, a highly potent and selective histamine H3-receptor agonist. Curi: Med. Chem. (2001) 8:1329–1340.
  • •Review on H3 receptor azomethine pro-drugs.
  • STARK H, KRAUSE M, ROULEAU A, GARBARG M, SCHWARTZ JC, SCHUNACK W: Enzyme-catalyzed pro-drug approaches for the histamine H3-receptor agonist (M-a-methylhistamine. Bioorg. Med. Chem. (2001) 9:191–198.
  • SASSE A, STARK H, REIDEMEISTER S et al.: Novel partial agonists for the histamine H3 receptor with high M vitro and in vivo activity.' Med. Chem. (1999) 42.4269–4274.
  • •First paper on lipophilic non-arninergic agonists for the H3 receptor.
  • SASSE A, LIGNEAU X, ROULEAU A et at Influence of bulky substituents on histamine H3 receptor agonist/antagonist properties. I Med. Chem (2002) 45:4000–4010.
  • PELLOUX-LEON N, FKYERAT A, TERTIUK W et al.: Potent partial agonists for the histamine H3 receptor lacking a nitrogen atom in the side chain. 29th Meeting of the European Histamine Research Society Nemi (Rome), Italy (2000) Abstract 31.
  • KENAKIN TP: Pharmacological proteus? Trends Pharmacol Sci. (1995) 16:256–258.
  • FOX GB, PAN JB, ESBENSHADE TA et al.: Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav. Brain Res. (2002) 131(1-2):151–161.
  • ANICHTCHIK OV, HUOTARI M, PEITSARO N, HAYCOCK JW, MANNISTO PT, PANULA P: Modulation of histamine H3 receptors in the brain of 6-hydroxydopamine-lesioned rats. Ear. .1. Neurosci. (2000) 12(11):3823–3832.
  • PASSANI MB, BLANDINA P: The neuronal histaminergic system in cognition. Curr. Med. Chem. Cen. Nerv. Syst. Agents [In press].
  • •Recommendable review on histaminergic system in cognition.
  • HALPERN MT: GT-2331 (Gliatech., Inc.). CLIFF. Opin. Centr. Peripher. Nerv. Syst. Invest. Drugs (1999) 1:524–527.
  • FLETCHER L: Guilford halts Gliatech deal. Nat. Biotech. (2000) 18(10):1023.
  • PILLOT C, ORTIZ J, HERON A, RIDRAY S, SCHWARTZ JC, ARRANG JM: Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J. Neurosci. (2002) 22(16):7272–7280.
  • •H3 receptor antagonists as potential neuroleptics or additives to them.
  • PILLOT C, HERON A, SCHWARTZ JC, ARRANG JM: Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. Eur. Neurosci (2003) 17(2):307–314.
  • LINTUNEN M, HYYTIA P, SALLMEN T et al.: Increased brain histamine in an alcohol-preferring rat line and modulation of ethanol consumption by H3 receptor mechanisms. FASEB (2001)15(6):1074–1076.
  • MORI T, NARITA M, ONODERA K, SUZUKI T: Modulation of the discriminative stimulus effects of cocaine and methamphetamine by the histaminergic system. Nihon Shinkei Seishin Yakurigaku Zasshi (2002) 22(3):73–78.
  • RYU JH, YANAI K, ZHAO XL, WATANABE T: The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3-receptors following destruction of the ascending dopaminergic neurones. Br.j Pharmacol (1996) 118(3):585–592.
  • KUBOTA Y, ITO C, SAKURAI E, SAKURAI E, WATANABE T, OHTSU H: Increased methamphetamine-induced locomotor activity and behavioral sensitization in histamine-deficient mice. Neurochem. (2002) 83(4):837–845.
  • TOYOTA H, DUGOVIC C, KOEFLL M et al.: Behavioral characterization of mice lacking histamine H3 receptors. Mol. Phannacol. (2002) 62(2):389–97; Erratum: Pharmacol (2002) 62(3):763.
  • ••First paper describing H3I- mice.
  • TAKAHASHI K, SUWA H, ISHIKAWA T, KOTANI H: Targeted disruption of H3 receptors results in change in brain histamine tone leading to an obese phenotype. " Clin. Invest. (2002) 110:1791–1799.
  • FOX GB, PAN JB, ESBENSHADE TA et al.: Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model. Phannacol. Biochem. Behav. (2002) 72(3):741–750.
  • FOX GB, PAN JB, RADEK RJ et al: Twonovel and selective non-imidazole H3 receptor antagonists A-304121 and A-317920: II. in vivo behavioral and neurophysiological characterization. Pharmacol Exp. Ther. (2003) [In press].
  • •Paper describing numerous in vivo effects of non-imidazole H3 receptor antagonists.
  • VOHORA D, PAL SN, PILLAI KK: Histamine and selective H3-receptor ligands: a possible role in the mechanism and management of epilepsy. Phannacol. Biochem. Behav. (2001) 68(4):735–741.
  • YOSHIDA M, NOGUCHI E, TSURU N: Lack of substantial effect of the H3-antagonist thioperamide and of the non-selective mixed H3-antagonist/H1-agonist betahistine on amygdaloid kindled seizures. Epilepsy Res. (2000) 40(2-3):141–145.
  • ESCHUN G, BAUTISTA E, DUKE K et al.: Effect of histamine H3 receptor blockade on venous return and splanchnic hemodynamics in experimental bacteremia. Grit. Care Med. (2002) 30(3):628–636.
  • TOZER MJ, BUCK IM, COOKE T, KALINDJIAN SB, PETHER MJ, STEEL KI: w-amidaz01-4-yBalkane-1-sulfonamides: a new series of potent histamine H3 receptor antagonists. Bioorg. Med. Chem. (2002) 10(2):425–432.
  • GRASSMANN S, SADEK B, LIGNEAU X et al.: Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H3-receptor antagonists. Eur. I Pharm. ScL (2002) 15(4):367–378.
  • ASLANIAN R, MUTAHI MW, SHIH NY: Identification of an novel, orally bioavailable histamine H3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-34) template. Bioorg. Med. Chem. Lett. (2002) 12:937–941.
  • •Novel chain replacement in H3 receptor antagonists.
  • BERTINARIA M, DI STILO A, TOSCO P et al.: [3-(1H-Imidazol-4-yl)propylguanidines containing furoxan moieties: a new class of H3-antagonists endowed with NO-donor properties. Bioorg. Med. Chem. (2003) 11:1197–1205.
  • GRABMANN S, APELT J, SIPPL W et al.: Imidazole derivatives as a novel class of hybrid compounds with inhibitory N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorg. Med. Chem. (2003) 11:2163–2174.
  • YANG R, HEY JA, ASLANIAN R, RIZZO CA: Coordination of histamine H3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology (2002) 66(3):128–135.
  • ARRANG JM, GARBARG M, QUACH TT, DAM TRUNG TUONG M, YERAMIANE, SCHWARTZ JC: Actions of betahistine at histamine receptors in the brain. Eur. Pharmacol (1985) 111(1):73–84.
  • TIGHILET B, TROTTIER S, MOURRE C, CHOTARD C, LACOUR M: Betahistine dihydrochloride interaction with the histaminergic system in the cat: neurochemical and molecular mechanisms. Eur.j Pharmacol (2002) 446(1-3):63–73.
  • KATHMANN M, SCHLICKER E, GOTHERT M: Intermediate affinity and potency of clozapine and low affinity of other neuroleptics and of antidepressants at H3 receptors. Psychopharmacology (Ben) (1994) 116(4):464–468.
  • AZUMA H, SAWADA S,TAKEUCHI S, HIGASHIYAMA K, KAKIGI A, TAKEDA T: Expression of mRNA encoding the H1, H2 and H3 histamine receptors in the rat cochlea. NemoReport (2003) 14(3):423–425.
  • GANELLIN CR, LEURQUIN F, PIRIPITSI A et al.: Synthesis of potent non-imidazole histamine H3-receptor antagonists. Arch. Pharm. (Weinheim) (1998) 331(12):395–404.
  • •First paper on potent non-imidazole H3 receptor antagonists.
  • WALCZYNSKI K, GURYN R, ZUIDERVELD OP, TIMMERMAN H: Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-piperaziny1)- and 2- (hexahydro-1H-1,4-diazepin-1- yl)benzothiazole derivatives as H3-antagonists with H1 blocking activities. Farmaco (1999) 54(10):684–694.
  • WALCZYNSKI K, GURYN R, ZUIDERVELD OP, TIMMERMAN H: Non-imidazole histamine H3 ligands. Part 2. New 2-substituted benzothiazoles as histamine H3 antagonists. Arch. Pharm. ffeinheiml (1999) 332(11):389–398.
  • LINNEY ID, BUCK IM, HARPER EA et at.: Design, synthesis and structure-activity relationships of novel non-imidazole histamine H3 receptor antagonists. Med. Chem. (2000) 43(12):2362–2370.
  • LAZEWSKA D, KIEC- KONONOWICZ K, PERTZ HH, STARK H, SCHUNACK W, ELZ S: Piperidine-containing histamine H3-receptor antagonists of the carbamate series: variation of the spacer length. Pharmazie (2001) 56(12):927–932.
  • METER G, LIGNEAU X, PERTZ HH et al.: Piperidino-hydrocarbon compounds as novel non-imidazole histamine H3-receptor antagonists. Bioorg. Med. Chem. (2002) 10(8):2535–2542.
  • LAZEWSKA D, KIEC- KONONOWICZ K, PERTZ HH, ELZ S, STARK H, SCHUNACK W: Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality. Pharmazie (2002) 57(12):791–795.
  • METER G, APELT J, REICHERT U et al: Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur. .1 Pharm. Sci. (2001) 13(3):249–259.
  • •Imidazole replacement in different classes of H3 receptor antagonists.
  • LIEDTKE S, FLAU K, KATHMANNM et al.: Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists. Naunyn Schmiedeberg 's Arch. Pharmacol (2003) 367(1):43–50.
  • SHAH C, MCATEE L, BREITENBUCHER JG et al.: Novel human histamine H3 receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12:3309–3312.
  • FAGHIH R, DWIGHT W, VASUDEVAN A et al: Aminoalkylbiphenylnitrils as histamine-3 receptor ligands. Bioorg. Med. Chem. Lett. (2002) 12:3077–3079.
  • FAGHIH R, DWIGHT W, GENTLES R et al.: Structure-activity relationships of non-imidazole H3 receptor ligands. Part 1. Bioorg. Med. Chem. Lett (2002) 12(15):2031–2034.
  • FAGHIH R, DWIGHT W, BLACK Let al.: Structure-activity relationships of non-imidazole H3 receptor ligands. Part 2: binding preference for D-amino acids motifs. Bioorg. Med. Chem. Lett. (2002) 12(15):2035–2037.
  • ESBENSHADE TA, KRUEGER KM, MILLER TR et al.: Two novel and selective non-imidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitropharmacological effects.' Pharmacol Exp. Ther. (2003) [In press].
  • •Different efficacies of inverse agonism for H3 receptor antagonists.
  • LIGNEAU X, MORISSET S,TARDIVEL-LACOMBE J et al.: Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain. Br. J. Pharmacol (2000) 131(7):1247–1250.
  • STARK H, SIPPLW, LIGNEAU X et al.: Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg. Med. Chem. Lett. (2001) 11(7):951–954.
  • UVEGES AJ, KOWAL D, ZHANG Yet al.: The role of transmembrane helix 5 in agonist binding to the human H3 receptor. Pharmacol. Exp. Ther: (2002) 301(2):451–458.
  • TING P, LEE J, ALBANESE M et al: The synthesis of substituted fluorenes as novel non-imidazole histamine H3 inhibitors. Bioorg. Med. Chem. Lett. (2002) 12(18):2643–2646.
  • MIKO T, LIGNEAU X, PERTZ HH et al.: Novel nonimidazole histamine H3 receptor antagonists: 1- (4- (phenoxymethyl)benzyl) piperidines and related compounds. I Med. Chem. (2003) 46:1523–1530.
  • CANGIOLI I, BALDI E, MANNAIONI PF et al.: Activation of histaminergic H3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release. Eat Neurosci. (2002) 16(3):521–528.
  • APELT J, LIGNEAU X, PERTZ HH et al.: Development of a new class of non-imidazole histamine H3 receptor ligands with combined inhibitory histamine N-methyltransferase activity.J Med. Chem. (2002) 45(5):1128–1141.
  • •Paper describing extremely potent H3 receptor antagonist and HMT inhibitors.
  • LEURS R, TLTLP MT, MENGE WM, ADOLFS MJ, ZUIDERVELD OP, TIMMERMAN H: Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed. Br:J. Pharmacol (1995) 116(4):2315–2321.
  • ALLEN MC: Agonist and antagonist effects of histamine H3 receptor ligands on 5-HT3 receptor-mediated ion current in NG 108-15 cells. Eur.j Pharmacol (1998) 361(2-3):261–268.
  • VOROBJEV VS, SHARONOVA IN, WALSH IB, HAAS HL: Histamine potentiates N-methyl-D-aspartate responses in acutely isolated hippocampal neurons. Neuron (1993) 11:837–844.
  • •First paper on histamine compounds acting at NMDA receptors.
  • BEKKERS JM: Enhancement of histamine of NMDA-mediated synaptic transmission in the hippocampus. Science (1993) 261:104–106.
  • SHIN N, COATES E, MURGOLO NJ et al.: Molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor. Mal Pharmacol. (2002) 62:38–47.
  • LIU C, MA XJ, JIANG X et al.: Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. MM. Pharmacol (2001) 59(3)420–426.
  • •Pharmacological characterisation of H4 receptor.
  • HOFSTRA CL, DESAI PJ, THURMOND RL, FUNG-LEUNG WP: Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol Exp. The,: (2003) [In press].
  • O'REILLY M, ALPERT R, JENKINSON S: Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. Recept. Signal Transduct. Res. (2002) 22(1-4):431–448.
  • GANTNER F, SAKAI K, TUSCHE MW, CRUIKSHANK WW, CENTER DM, BACON KB: Histamine H4 and H2 receptors control histamine-induced interleukin-16 release from human CD8+ T cells.' Phannacol. Exp. The]: (2002) 303(1):300–307.
  • LIU C, WILSON SJ, KUEI C, LOVENBERG TW: Comparison of human, mose, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. .1. Pharmacol Exp. The]: (2001) 299(1):121–130.
  • •Species variation within H4 receptors.
  • HATTON GLYANG QZ : Ionotropic histamine receptors and H2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling.' Neurosci. (2001) 21(9):2974–2982.
  • KAZUTA Y, HIRANO K, NATSUME K et al.: Cyclopropane-based conformational restriction of histamine. (1S,23)-2- (2-Aminoethy0-1- (1H-imidazol-4-y0 cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cir-cyclopropane structure." Med. Chem (2003) 46:1980–1988.
  • KOYAMA M, SEYEDI N, FUNG-LEUNG WP, LOVENBERG TW, LEVI R: Norepinephrine release from the ischemic heart is greatly enhanced in mice lacking histamine H3 receptors. Mol. Pharmacol (2003) 63(2):378–382.
  • FAGHIH R, DWIGHT W, PAN JB et al: Synthesis and SAR of aminoalkyloxy-biary1-4-carboxamides: novel selective histamine H3 receptor antagonist. Bioorg. Med. Chem. Lett. (2003) 13(7):1325–1328.
  • MILLAN-GUERRERO RO, PINEDA-LUCATERO AG, HERNANDEZ-BENJAMIN T, TENE CE, PACHECO MF: Na-methylhistamine safety and efficacy in migraine prophylaxis: Phase I and Phase II studies. Headache (2003) 43:389–394.
  • ZARAGOZA F, STEPENSON H, BYWATER RP et al: Discovery of NNC 0038-0000-1049, a new and potent histamine H3 receptor antagonist. 32nd Annual Meeting of the European Histamine Research Socieo,. Noordwijkerhout, The Netherlands (2003) Abstract 88.

Website

  • http://www.gper.org/7tm/htm1s/entries.htm1 GPCR database.
  • http://www.gper.org/7tm/seq/a11/ HH3R_HUMAN.SW.html GPCR database for histamine H3 receptor.
  • http://www.4adi.com/data/histamine/ hr14seq. html Sequence alignment of histamine subreceptors.
  • http://bioinf.man.ac.uk/dbbrowser/ gperPRINTS/PRO1471.html Protein fingerprint database for histamine H3 receptor.
  • http://www.gper.org/7tm/seq/a11/ HH4R_HUMAN.SW.html GPCR data base for histamine H4 receptor.
  • http://www.genmapp.org/IVIAPPSet-Human/GPCRDB_MAPPs/_Support/ Hs_GPCRs_Other/HRH4_Q9H3N8.htm Gene mapping of histamine H4 receptors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.